Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 280

1.

Effects of short-term and long-term pretreatment of Schisandra lignans on regulating hepatic and intestinal CYP3A in rats.

Lai L, Hao H, Wang Q, Zheng C, Zhou F, Liu Y, Wang Y, Yu G, Kang A, Peng Y, Wang G, Chen X.

Drug Metab Dispos. 2009 Dec;37(12):2399-407. doi: 10.1124/dmd.109.027433. Epub 2009 Sep 9.

PMID:
19741040
[PubMed - indexed for MEDLINE]
Free Article
2.

Integral pharmacokinetics of multiple lignan components in normal, CCl4-induced hepatic injury and hepatoprotective agents pretreated rats and correlations with hepatic injury biomarkers.

Xie Y, Hao H, Kang A, Liang Y, Xie T, Sun S, Dai C, Zheng X, Xie L, Li J, Wang G.

J Ethnopharmacol. 2010 Sep 15;131(2):290-9. doi: 10.1016/j.jep.2010.06.038. Epub 2010 Jun 30.

PMID:
20600750
[PubMed - indexed for MEDLINE]
3.

In vivo inhibition of CYP3A-mediated midazolam metabolism by anchusan in rats.

Saito Y, Nishimura Y, Kurata N, Iwase M, Aoki K, Yasuhara H.

J Pharmacol Sci. 2011;115(3):399-407. Epub 2011 Feb 24.

PMID:
21358120
[PubMed - indexed for MEDLINE]
Free Article
4.

Effects of continuous ingestion of herbal teas on intestinal CYP3A in the rat.

Matsuda K, Nishimura Y, Kurata N, Iwase M, Yasuhara H.

J Pharmacol Sci. 2007 Feb;103(2):214-21. Epub 2007 Feb 8.

PMID:
17287587
[PubMed - indexed for MEDLINE]
Free Article
5.

Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite.

Zhang X, Quinney SK, Gorski JC, Jones DR, Hall SD.

Drug Metab Dispos. 2009 Aug;37(8):1587-97. doi: 10.1124/dmd.109.026658. Epub 2009 May 6.

PMID:
19420129
[PubMed - indexed for MEDLINE]
Free Article
6.

Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.

Granvil CP, Yu AM, Elizondo G, Akiyama TE, Cheung C, Feigenbaum L, Krausz KW, Gonzalez FJ.

Drug Metab Dispos. 2003 May;31(5):548-58.

PMID:
12695342
[PubMed - indexed for MEDLINE]
Free Article
7.

The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.

Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, Hall SD.

Clin Pharmacol Ther. 2003 Sep;74(3):275-87. Erratum in: Clin Pharmacol Ther. 2004 Mar;75(3):249.

PMID:
12966371
[PubMed - indexed for MEDLINE]
8.

Determination of the enzyme(s) involved in the metabolism of amiodarone in liver and intestine of rat: the contribution of cytochrome P450 3A isoforms.

Shayeganpour A, El-Kadi AO, Brocks DR.

Drug Metab Dispos. 2006 Jan;34(1):43-50. Epub 2005 Oct 4.

PMID:
16204463
[PubMed - indexed for MEDLINE]
Free Article
9.

Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.

Kharasch ED, Walker A, Hoffer C, Sheffels P.

Clin Pharmacol Ther. 2004 Nov;76(5):452-66.

PMID:
15536460
[PubMed - indexed for MEDLINE]
10.

Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin.

Quinney SK, Zhang X, Lucksiri A, Gorski JC, Li L, Hall SD.

Drug Metab Dispos. 2010 Feb;38(2):241-8. doi: 10.1124/dmd.109.028746. Epub 2009 Nov 2.

PMID:
19884323
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.

Chaobal HN, Kharasch ED.

Clin Pharmacol Ther. 2005 Nov;78(5):529-39.

PMID:
16321619
[PubMed - indexed for MEDLINE]
12.

In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies.

Prueksaritanont T, Kuo Y, Tang C, Li C, Qiu Y, Lu B, Strong-Basalyga K, Richards K, Carr B, Lin JH.

Drug Metab Dispos. 2006 Sep;34(9):1546-55. Epub 2006 Jun 16.

PMID:
16782766
[PubMed - indexed for MEDLINE]
Free Article
13.

[A limited sampling strategy of phenotyping probe midazolam to predict inhibited activities of hepatic CYP3A in rats].

Zhu XH, Jiao JJ, Zhang CL, Lou JS, Liu CX.

Yao Xue Xue Bao. 2008 Sep;43(9):905-11. Chinese.

PMID:
19048780
[PubMed - indexed for MEDLINE]
14.

Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats.

Kanazu T, Yamaguchi Y, Okamura N, Baba T, Koike M.

Xenobiotica. 2004 May;34(5):403-13.

PMID:
15370957
[PubMed - indexed for MEDLINE]
15.

Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats.

Hirunpanich V, Murakoso K, Sato H.

Int J Pharm. 2008 Mar 3;351(1-2):133-43. Epub 2007 Oct 5.

PMID:
18082981
[PubMed - indexed for MEDLINE]
16.

Differential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in rat.

Eeckhoudt SL, Horsmans Y, Verbeeck RK.

Xenobiotica. 2002 Nov;32(11):975-84.

PMID:
12487727
[PubMed - indexed for MEDLINE]
17.

Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.

Yamano K, Yamamoto K, Katashima M, Kotaki H, Takedomi S, Matsuo H, Ohtani H, Sawada Y, Iga T.

Drug Metab Dispos. 2001 Apr;29(4 Pt 1):443-52.

PMID:
11259329
[PubMed - indexed for MEDLINE]
Free Article
18.

Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in rats.

Zhang X, Galinsky RE, Kimura RE, Quinney SK, Jones DR, Hall SD.

Drug Metab Dispos. 2010 Jan;38(1):61-72. doi: 10.1124/dmd.109.028290. Epub .

PMID:
19797607
[PubMed - indexed for MEDLINE]
Free Article
19.

In vivo approach for the evaluation of mechanism-based inhibition of cytochrome P450 3A in rats.

Sekiguchi N, Kato M, Takada M, Watanabe H, Higashida A, Sakai S, Ishigai M, Aso Y.

Xenobiotica. 2008 Apr;38(4):368-81. doi: 10.1080/00498250701851891 .

PMID:
18340562
[PubMed - indexed for MEDLINE]
20.

In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A.

Polasek TM, Sadagopal JS, Elliot DJ, Miners JO.

Eur J Clin Pharmacol. 2010 Mar;66(3):275-83. doi: 10.1007/s00228-009-0760-2. Epub 2009 Dec 11.

PMID:
20012430
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk